medical decision support medical decision support
Sign In

Evidence Scoring (ES) System of Yamazaki for Comparing the Strength of Evidence for a Drug in Large Scale Clinical Trials

Purpose: To evaluate the strength of evidence for a drug tested in a large scale clinical trial using the Evidence Score (ES) of Yamazaki et al.

Description

Yamazaki developed the Evidence Scoring (ES) System for rating the strength of evidence for a drug tested in large scale clinical trials. This can help provide guidance for best clinical practice and to reduce bias. The author is from the University of Tokyo.


 

Parameters:

(1) significant clinical advantage

(2) control arm

 

Significant Clinical Advantage

Control Arm

Evidence Score

shown in primary endpoint

active comparator

8

shown in primary endpoint

placebo

4

shown in secondary or other endpoint

active comparator

2

shown in secondary or other endpoint

placebo

1

not shown

NA

0

not tested or data not available

NA

N

 

Interpretation:

• minimum evidence score: 0

• maximum evidence score: 8

• The higher the score the greater the evidence for a clinical advantage.

• If multiple clinical trials are being considered, the ESs for all of the clinical trials can be added up.


To read more or access our algorithms and calculators, please log in or register.

Objective

ICD-10